Completed PHASE1 INTERVENTIONAL 3-arm NCT02359877

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Sponsor: Biocad

Conditions Healthy

Updated 7 times since 2017 Last updated: Apr 7, 2017 Started: Jul 31, 2014 Primary completion: Oct 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02359877, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Biocad, it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

May 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — May 2017 [monthly]

Completed PHASE1

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biocad

Data source: Biocad

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint Petersburg, Russia